Patient eligibility
NSCLC
NSCLC
The present trial, JMTO LC14‐01, was a multi‐institutional study and was designed as a randomized, phase II trial to be performed in wide area of Japan. The protocol was approved by the independent ethics committees of participating institutions. This trial was conducted in accordance with the Ethical Guidelines for Medical and Health Research involving Human Subjects, the Declaration of Helsinki, and the Clinical Trials Act in Japan. Written informed consent was obtained from all patients. This trial was registered with the UMIN Clinical Trials Registry (UMIN000016932) and the Japan Registry of Clinical Trials (jRCTs031180214).For patients with previously treated stage IIIB‐IV or postoperative relapsed NSCLC, at least one of the previous treatment regimens had to have contained platinum‐based combination chemotherapy. In patients with 